Archive for August, 2021
Nuclear safety regulators in the United States and Canada recently concluded their collaborative project, which focused on small modular reactor licensing. The U.S. Nuclear Regulatory Commission and the Canadian Nuclear Safety Commission have released a joint report that offers feedback on the manufacturing codes it suggests for use in both Canada and the U.S. for the Xe-100 reactor pressure vessel design.
The report is the first result of the program of cooperation that the U.S. Nuclear Regulatory Commission and the Canadian Nuclear Safety Commission entered into in August 2019. At the time, President Rumina Velshi of Canada’s nuclear commission stated that global advances and interests in advanced and small modular reactors was growing rapidly, which was why the U.S. and Canada were working together to ensure the deployment and development of these technologies was done efficiently and safely.
The agreement between the two regulators has allowed both commissions to take into consideration the insights and results produced by the technical reviews of reactor designs. During this project, the regulators combined efforts to evaluate a paper submitted by X-energy last year, which contained the manufacturing codes the firm planned to use in its Xe-100 high temperature reactor pressure vessel design.
The Xe-100 is an 80 megawatt electrical high temperature gas-cooled reactor that will be manufactured in packs of four. The reactor is taking part in the Advanced Reactor Demonstration Program, which is being held by the U.S. Department of Energy. In addition to this, it’s undergoing vendor design review with the Canadian Nuclear Safety Commission.
X-energy planned to design the reactor vessel to meet the requirements of a specific code that was issued by the ASME (American Society of Mechanical Engineers) but manufacture it to meet the quality requirements and assurance of another ASME code and brand it as such.
The company proposed that the reactor be manufactured both at the Darlington power plant under Ontario Power Generation and the Columbia power plant under Energy Northwest. For more details, you can access the joint report here.
Both regulators came to the conclusion that the approach was feasible, provided the company included some additional technical justifications, which were stated in the report and addressed the regulators’ observations which were mentioned in the document. In their report, the regulators stated that the suggested approach could be used to establish criteria for the Xe-100 high temperature reactor’s pressure vessel design and manufacture.
The Canadian Nuclear Safety Commission also noted that their feedback was informal and would not be used in any regulatory decision making.
As such collaborations take root among different countries, the penetration of nuclear energy is likely to increase, and that could create an even bigger market for uranium extraction companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR).
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced it will host the first-ever Sequire EdTech Conference, a one-day investor event featuring prominent virtual work and remote learning companies. The conference is slated to take place from 11:30 a.m. to 5:30 p.m. ET on Sept. 13, 2021. Amesite is the premium sponsor for the event that will feature many influential speakers in the space in addition to 10+ edtech companies. “Edtech has changed forever, and corporations have quickly changed the way they are training their employees,” said Christopher Miglino, founder and CEO of SRAX. “There is a great group of companies that are transforming this sector, many of which we have the pleasure of hosting at this event. We look forward to having you join us.”
To view the full press release, visit https://ibn.fm/Gw3iN
About SRAX Inc.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and www.MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, has reported its second quarter 2021 financials. The report includes the news that adjusted sales for the first six months reached $58.5 million, with revenue for Q2 2021 topping $13.3 million compared to $11.8 million in Q1 2021, an increase of 13%. The company’s gross margin for the period was $9.5 million. The company also noted that it was able to reduce its short-term obligations through repayment of approximately $18 million of debt and restructuring of more than $20 million into long-term debt. Corporate highlights for RWBYF include closing on the acquisition of Acreage Florida, a property that is licensed to operate medical marijuana dispensaries, which includes processing facility and a cultivation facility, as well as obtaining 30 double-wide, fully enclosed cultivation pods that will provide approximately 19,000 square feet of turnkey cultivation space. The company also has completed the more comprehensive portion of Michigan’s two-step application process for medical marijuana licensing through a wholly owned operating subsidiary. “We continue to make great strides with our branded products and see momentum in Q2, which has teed up Q3 nicely, and will translate into a strong second half,” said Red White & Bloom chair and CEO Brad Rogers in the press release. “In Florida, after closing the acquisition at the end of April, we have made strategic investments that are allowing us to quickly ramp up capacity as well as complete construction for new store openings before the end of 2021. Under IFRS, revenue for the second quarter was up 13% over the first quarter of this year. Even with the growth in recognized revenue, it’s important to note that in the second quarter, there were a number of significant raw material inventory purchases made to support growth for Q3 and in anticipation of new branded product line launches; we want to point out that, under IFRS, these purchases reduced recognized revenue for PV in Michigan. We continue to present the Adjusted Sales to assist investors in understanding the growth and demand for our brands in the US cannabis market.”
To view the full press release, visit https://ibn.fm/hiv5y
About Red White & Bloom Brands Inc.
Red White & Bloom Brands is positioning itself to be one of the top-three, multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on major U.S. markets, including Michigan, Illinois, Massachusetts, Arizona and California, with respect to cannabis, as well as the United States and internationally for hemp-based CBD products. For more information about the company, please visit www.RedWhiteBloom.com.
NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at http://ibn.fm/RWBYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a diversified leading provider of augmented reality (“AR”) experience technologies and services, today announced the expansion of its partnership with Kohl’s Corporation (NYSE: KSS), one of the largest department store chains in the United States. The partnership began when Kohl’s identified Threedy.ai, now part of Nextech, and its WebAR for Ecommerce solutions as the most attractive option to introduce augmented reality and 3D models into its customer experience. Extensive product testing that began with Kohl’s Innovation Center validated Threedy’s return on investment. According to the update, Kohl’s, in collaboration with Nextech, is now significantly scaling WebAR for Ecommerce, creating thousands of new 3D models that will enhance the augmented reality experience for Kohl’s customers. “Kohl’s is an example of a large retailer that quickly recognized the potential for WebAR to enhance its online business,” said Evan Gappelberg, CEO of Nextech. “Augmented reality in e-commerce can not only drive sales, but reduce customer returns as the buyer feels a higher level of product familiarity before placing the order — the latter being a key point for many e-commerce customers. By combining Threedy’s disruptive AI technology and our leading AR platform, large retailers like Kohls can reach the necessary scale critical to support their e-commerce business.”
To view the full press release, visit https://ibn.fm/t744z
About Nextech AR Solutions Corp.
Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360° portals to its audiences, altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance), as well as learning and training experiences. Nextech focuses on developing AR solutions; however, most of the company’s revenues are currently derived from three ecommerce platforms, VacuumCleanerMarket.com (“VCM”), InfinitePetLife.com (“IPL”) and TruLyfeSupplements.com (“TruLyfe”), as well as VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, visit www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Net Element (NASDAQ: NETE), a global technology and value-added solutions group that supports electronic payments, today announced that its stockholders have approved the proposed merger of the company’s wholly owned entity with Mullen Automotive Inc. (the “merger”). According to the update, a majority of the votes cast were in favor of the merger. The company will proceed to work on the final requirements to conclude the transaction with Mullen Automotive as referenced in the company’s Form S-4/proxy statement and the merger filings of the company with the Securities and Exchange Commission.
To view the full news release, visit https://ibn.fm/oQ2Lu
About Net Element Inc.
Net Element operates a payments-as-a-service transactional and value-added services platform for small and medium enterprises (“SMEs”) in the U.S. and selected emerging markets. In the U.S., the company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017, it was recognized by South Florida Business Journal as one of 2016’s fastest-growing technology companies. For additional information, visit www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
For most of the young electric vehicle (“EV”) industry’s life, insufficient charging infrastructure has been a major hurdle to EV adoption. Increasingly restrictive emission standards are forcing automakers to electrify their vehicle lines, but drivers are unwilling to switch to EVs because of the limited number of public charging stations. Consequently, the current administrations are looking to invest millions of dollars into developing a reliable public EV charging network.
Louisiana will soon be the recipient of some of these funds, allowing it to install charging stations in more than a dozen universities, government agencies and electric utilities across the state. The Department of Environmental Quality awarded 26 grants worth more than $1.7 million to install 82 charging stations across the state. The money was sourced from Louisiana’s $19.8 million share of the gargantuan $4.3 billion fine Volkswagen paid the U.S. Justice Department after a federal criminal investigation found that the German automaker had lied on vehicle emission states.
A large percentage of Louisiana’s share of the Volkswagen settlement will go toward green energy and electrification, with an additional $12 million being used to replace 351 diesel-powered buses owned by 16 school boards with electric alternatives. Furthermore, $7.3 million has been awarded to the state Department of Transportation and Development as well as the Department of Agriculture to replace their old diesel vehicles and equipment. Since low and zero-emission vehicles tend to cost an arm and leg, a majority of drivers simply cannot afford to go electric, especially without generous subsidies and incentives.
Fleets, however, are a different story altogether as the organizations behind them, whether it’s a delivery company or a university, usually have enough funds to purchase a fleet of electrified vehicles and install charging infrastructure. Thanks to the new drivetrains, Louisiana will be looking at reduced greenhouse gas emissions including carbon, nitrogen oxide, sulfur dioxide, particulate matter and volatile organic compounds. These new grants, sourced from Volkswagen’s settlement money, are meant to help entities that are looking to buy electric vehicles or have already purchased electric vehicles by funding the development of three levels of EV charging stations.
Organizations that receive the grants will be able to install level 2 light-duty EV charging stations that use 240-cycle electricity to charge EV batteries over several hours, a DC (direct current) version that can fast-charge an EV battery in just 30 minutes, or a paratransit charging station that can charge several vehicles simultaneously. Some of the schools that will receive these chargers include Southeastern Louisiana University, Southern University, LSU, Xavier University, Sowela Technical Community College and Nicholls State.
The synergy between favorable governmental action and the involvement of for-profit companies such as Ideanomics Inc. (NASDAQ: IDEX) is likely to speed up EV adoption at a higher rate than would have been possible without those different efforts pushing in the same direction.
NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
- On August 25, FingerMotion held a conference call in which it provided updates on the progress of its Sapientus division, application to uplist to the NASDAQ, and more
- Hosted by FingerMotion CEO Martin Shen, the corporate update also included a review of the Q1 2022 results, which marked the fourth consecutive quarter of record revenue
- FingerMotion received its first comment letter from NASDAQ, to which it responded promptly and efficiently
- The company, in collaboration with its partners, has begun translating products under the Sapientus division into an actual operational pilot
- FNGR will hold an AGM in November
In July last year, FingerMotion (OTCQX: FNGR) launched Sapientus, its Big Data Insights arm and third operational division, built to deliver data-driven insights and solutions for companies and businesses in the insurance and financial services sectors (https://ibn.fm/fMJF6).
Since then, the division has grown in many ways. For instance, it witnessed two consecutive quarters of revenue generation during Q4 2021 and Q1 2022 and quarter-over-quarter revenue growth during the latter reporting period (https://ibn.fm/qWjm2). Additionally, earlier this year, FNGR reported an agreement between Sapientus and Pacific Life Re-Insurance to provide cutting-edge behavioral risk analytics for the insurance company (https://ibn.fm/xSnGM). So, what further progress has the division made since then?
In an August 25 conference call, whose recording is available on the company’s website (https://ibn.fm/BnQra), FingerMotion CEO Martin Shen sought to answer this question as part of a corporate update aimed at informing shareholders and the general public about FNGR’s progress thus far and outlook for the future. Included in the August 25 update were the strides the Sapientus division has made, progress on the application to uplist on NASDAQ, a review of the Q1 2022 results, and general announcements.
Firstly, Martin discussed the Q1 2022 results for the three months ended May 31, 2021. Pleased with all facets of the business as all facets were growing tremendously, he observed that Q1 2022 represented the company’s fourth consecutive quarter of record revenue, having recorded revenue of $6 million. According to Shen, FingerMotion is optimistic that it will be a profitable business “fairly soon” and has set its sights on higher-margin verticals.
Regarding its uplist application to the Nasdaq Capital Market, FNGR focused on “getting it right the first time” by meeting most of the objective criteria and parameters. “To further bolster our own confidence, we received our first comment letter from Nasdaq fairly quickly, meaning we had met most of the parameters in the first place,” Shen added.
The company brought in an independent advisory firm, which collaborated with its in-house counsel to issue an efficient, fast response to the comment letter. Shen was, however, quick to caution viewers on the need to keep their optimism in check, given that several other hurdles are yet to be surmounted. Still, he expressed his pride in his team’s work so far, further noting the company’s commitment to promptly and efficiently answering all questions NASDAQ’s examiners send.
“The launch of Sapietus marked a significant milestone for our journey because we moved away from being a top-up company to this dynamic technology solution provider and allowed us to expand our company and business into insurance and then the wider financial industry in general,” Shen described Sapientus.
He continued, “Our distinctive edge and what we do as Sapientus is our ability to integrate all these publicly available data into these proprietary risk matrices with behavioral indicators derived from event-driven or even contextual-based information.”
Shen pointed out that Sapientus, which prioritizes privacy protection, uses advanced algorithms to generate distributional statistics and categorical variables agnostic to individual identity. Crucially, though, the data only contains demographic markers. By providing the desired level of customer understanding through behavioral analytics, Sapientus aims to supply actionable intelligence and facilitate the efficient delivery of services to various players within the insurance industry.
Working with partners such as Pacific Life Re-Insurance, FingerMotion has begun translating its Sapientus-based products into an actual operational pilot that benefits the service providers and customers alike. For insurance companies, it will provide value, enhance efficiencies, and lower the cost-of-service delivery. At the same time, it will eliminate existing pain points insurance customers had. Shen also outlined future development plans for the Sapientus division.
Lastly, FingerMotion announced its AGM scheduled for November and will provide additional updates on this in due course.
For more information, visit the company’s website at www.FingerMotion.com.
NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer
ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”), a wholly-controlled subsidiary of Cybin, has achieved certain milestones for Year 1 Q3 (iv)-(vi), as contemplated by the terms of a contribution agreement dated December 4, 2020 (the “ Transaction Agreement ”) among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “ Acquiror ”), a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia (the “ Adelia Shareholders ”).
Pursuant to the terms of the Transaction Agreement, 9,392.6 Class B common shares in the capital of the Acquiror (the “ Class B Shares ”) shall be issued to the Adelia Shareholders, in satisfaction of the $317,471.09 (approximately US $251,581.81) due to them on meeting a portion of the relevant milestones, at an effective issue price of $33.80 per Class B Share. The Class B Shares issued by the Acquiror to the Adelia Shareholders are exchangeable for common shares in the capital of Cybin (the “ Cybin Shares ”) on a 10 Cybin Shares for 1 Class B Share basis, at the option of the holder thereof, subject to customary adjustments. No Class B Shares are exchangeable prior to December 14, 2021, and not more than: (i) 33 1/3% of the Class B Shares will be exchangeable prior to December 14, 2022; (ii) 66 2/3% of the Class B Shares will be exchangeable prior to December 14, 2023; and (iii) thereafter, 100% of the Class B Shares will be exchangeable.
Additional information related to the transaction is available in the Transaction Agreement, which is filed under Cybin’s profile on SEDAR ( www.sedar.com ) and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov .
About Cybin
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and potential treatment regimens for psychiatric disorders.
Cautionary Notes and Forward Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. Forward looking statements in this news release include statements regarding the Company’s development of innovative drug delivery systems, novel formulation approaches and potential treatment regimens for psychiatric disorders and Adelia’s proprietary development strategy and development of medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company’s management’s discussion and analysis for the three months ended June 30, 2021 and the Company’s listing statement dated November 9, 2020, which are available under the Company’s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov . Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.
The Neo Exchange Inc. has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.
Unless otherwise indicated, all dollar amounts in this news release are expressed in Canadian dollars.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831006032/en/
Investor:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media:
John Kanakis
Cybin Inc.
John@cybin.com
The U.S Preventive Services Task Force recently issued a guideline recommending that people at average risk for colorectal cancer start undergoing screening exams when they’re 45, as opposed to the conventional 50 years. This recommendation was prompted by the recent increase in colorectal cancer cases in individuals who are below 50.
These changes, which were published on JAMA Network, align with recommendations from the American Cancer Society. Colorectal cancer is sometimes referred to as rectal cancer, colon cancer or bowel cancer. It usually begins in the rectum or colon, which make up part of the large intestine.
Most cases of colorectal cancer start as growths known as polyps on the inside lining of the rectum or colon. These polyps usually mutate into cancer over time. It should be noted that the likelihood of a polyp becoming cancerous is mainly dependent on the polyp type.
Colorectal cancer is among the most preventable malignancies, with data showing that since the 1980s, its overall incidence in people aged 50 and above has diminished, mainly due to increased screening. Colorectal cancer screening tests are widely available and can be used to detect the disease, which has a long natural history of progression, in its early stages.
Young-Onset Colorectal Cancer Center director Kimmie Ng stated that since the 1990s, there has been an increase in the incidence of colorectal cancer in people who are aged below 50. Data shows that rectal cancer and colon cancer diagnoses increased from 9% and 5% in 2010 to 15% and 11% respectively in 2020. The cause for the increase in young-onset colorectal cancer isn’t known.
Ng explains that decreasing the recommended age to begin screening would make colorectal cancer screening available to more individuals in the United States and save more lives by catching the disease in its early stages, in addition to preventing it.
The U.S. Preventive Services Task Force is financed by the Department of Health and Human Services and is made up of independent experts. The task force reviews evidence of efficaciousness of preventive services and gives recommendations. The panel of experts selected 45 as the age to begin screening based on research which shows that starting screening at that age prevents more early deaths in comparison with beginning screening at age 50. In their publication, the authors note that no change has been made to the task force’s 2016 guideline, which recommended that people between 76 and 85 years of age be screened.
The recommendation that the age at which colorectal cancer screening should begin be lowered is likely to increase the demand for those testing services. The innovative cancer screening technologies developed by companies such as AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) could come in handy to address that increased demand.
NOTE TO INVESTORS: The latest news and updates relating to AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) are available in the company’s newsroom at https://ibn.fm/ANPC
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
These days, anyone interested in trying cannabis has quite a wide range of product lines to choose from. Long gone are the days when the only cannabis product individuals could access was cannabis flower and poorly baked brownies, which was popularised by Alice B. Toklas in the 1960s. We’ve now got a plethora of different cannabis edible options, and anyone who have sampled different types of edibles know just how wildly different the experience can be. While the effects will generally be the same, regardless of the type of edible you consume, the onset of the effects and their longevity will often depend on the type of product.
Baked cannabis edibles were the most popular cannabis alternative for years, and for good reason. They require limited ingredients and are relatively easy to make. So for most people, their first foray into cannabis edibles involved baked goods. Why does cannabis work so well with cookies, cakes, banana bread, muffins and brownies? Cannabinoids, the chemical compounds responsible for cannabis’ effects, are fat and oil soluble, meaning they bind superbly with the oils used to make baked goods. Since the products have to first go through the gut then the liver, it will take around 30 minutes to an hour for the effects to kick in and once they do, can last anywhere from six to eight hours.
Chocolate infused with cannabis is a newer product that is gaining popularity. Chocolate also contains fat, hence it will readily bind with THC, although in lesser amounts compared to baked goods. But since chocolate doesn’t have to be baked or exposed to heat in general, the cannabinoids within retain most of their potency. Additionally, the chocolate will effectively hide the cannabis taste, which might put some individuals off, and is great for use in high doses as it is not as filling as baked goods.
Gummies are currently the most popular cannabis edibles in the country, ranking as the third-most searched for food in 2018. Cannabis-infused gummies come in a wide variety of flavors, can be used discreetly, and allow for easy dosing. On top of that, they are faster acting compared to other fat-heavy cannabis edibles, so the effects will kick in a little faster. Since gummies are usually made with cannabis distillate, they digest quickly, meaning the effects will peak sooner and taper off fast. Additionally, some companies will add terpenes to their gummies to provide more specific effects that mimic strain profiles.
Drinks infused with cannabis have gotten a lot better thanks to evolving technology. Nano emulsification has allowed companies to completely dissolve THC and CBD in water despite them not being water-soluble. Consequently, the market has been hit by a slew of smoothly infused cannabis beverages ranging from 5-10 mg in potency. There are a wide variety of flavors thanks to different THC, CBD, terpene and adaptogen formulations, and the cannabis beverages will kick in quickly and wear off faster than other cannabis edibles.
The difference in the way each cannabis edible affects consumers could explain why companies such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) offer a variety of those products so that each user can choose what suits them.
NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
TAAT(TM) (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) today announced that Green Global Earth (“GGE”), the exclusive TAAT(TM) distributor for the U.K. and Ireland who recently placed a CA$1,075,000 purchase order in addition to its previous CA$149,000 order, has issued an additional purchase order for €360,000 (approximately CA$536,000) for a full shipping container of TAAT to be distributed in Australia. According to the update and as previously announced, the company last year proactively applied for trademarks in Australia as well as dozens of international jurisdictions. With Australia having the highest average price of a tobacco cigarette pack in the world (the equivalent of US$25.12 for a 20-pack of Marlboro, compared to US$8.00 in the United States*), the company has long contemplated launching TAAT in this market to capitalize on its competitive price point as a non-tobacco product. Current estimates indicate that TAAT will retail for approximately 30% less than tobacco cigarettes in Australia.
To view the full press release, visit https://ibn.fm/d6Qsa
About TAAT(TM) Global Alternatives Inc.
The company has developed TAAT(TM), which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.
*https://www.statista.com/chart/15293/price-for-cigarettes-per-country/
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Save Foods (NASDAQ: SVFD), an agri-food-tech company focused on developing and selling eco-friendly products specifically designed to extend shelf life and ensure food safety of fresh fruits and vegetables, today announced the appointment of Dariela Farcas as director of Public Relations and Investor Relations. In this role, Dariela will be responsible for leading the company’s investor and public relations programs, as well as providing the investment community and other stakeholders with an accurate presentation of Save Foods’ products, growth strategy, business performance and market outlook. “I am so pleased that Dariela has agreed to join our team as director of PR & IR. As a newly listed Nasdaq company, it is critical that we continue to provide clear and consistent information to all of our stakeholders, investors, customers, the financial markets, the media and the general public,” said SVFD CEO David Palach. “Dariela’s experience in strategic planning and brand development, as well as her ability to communicate in English, Spanish and Hebrew, will be a major asset for the company as we work to build market awareness with a broader audience.”
To view the full press release, visit https://ibn.fm/ycqTN
About Save Foods Inc.
Save Foods is an innovative, dynamic company addressing two of the most significant challenges in the agri-food-tech industry: food waste and loss and food safety. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops new solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and the consumers alike. SVFD’s initial applications are in post-harvest treatments in fruit and vegetable packing houses processing citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of hazardous chemicals and their residues, Save Foods products not only prolong fresh produce shelf life and reduce food loss and waste, they also ensure a safe, natural and healthy product. For more information about the company, visit www.SaveFoods.co.
NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at http://ibn.fm/SVFD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) has announced its interim unaudited condensed consolidated financial results for the three months ended June 30, 2021. All amounts are reported in Canadian dollars unless otherwise specified. Among the highlights, the company generated $4,089,705 in gross revenue, an increase of $3,956,815 from the gross revenue generated in Q1 2021, as well as achieved a 28% gross margin compared to 23% in Q4 2021. “PlantX continues to invest its efforts and resources strategically to grow and meet the demand for our plant-based products,” said PlantX Founder Sean Dollinger. “It is encouraging to see the impact of our work. We are more committed than ever to continue building our business by executing on our mission and expansion goals.”
To view the full press release, visit https://ibn.fm/rrIwi
About PlantX Life Inc.
As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at www.PlantX.com and the PlantX investor website at https://Investor.PlantX.com.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
With several territories around the world poised to phase out conventional gas-powered cars in exchange for zero-emission electric vehicles (“EVs”), the automobile sector and ancillary industries are looking at a few decades of significant change from the status quo. Electric cars are fundamentally different from internal-combustion-engine (“ICE”) vehicles, from the lithium-ion battery packs that power them to the electric drivetrain, which has nearly a dozen parts, and the proprietary software that keeps the hardware running smoothly and efficiently. As carmakers build more electric vehicles in an effort to meet emission standards and electrify their lineups, the machine industry will be drowning in work.
Robot and factory equipment manufacturers saw demand for their products fall to $361.8 million last April amid the coronavirus pandemic, as did most industries, but the auto sector’s recovery bodes well for them. The U.S. Census Bureau says that the American machinery industry saw orders surge to $506 million by June, and we can expect orders to continue to rise as more automakers go electric and EVs fill the roads. Andrew Lloyd, the electromobility segment leader at Comau, an Italian manufacturing equipment supplier owned by Stellantis, says the company expects significant demand to come its way for the next 18 to 24 months.
Consequently, EV factories have drawn considerable attention from investors looking to cash in on the demand for electric vehicle parts, which according to Lloyd has yet to hit its climax. LMC Automotive predicts that automakers will pump more than $37 billion into North American manufacturing plants with more than 77% of the funds going to EV or SUV projects. Since Americans absolutely love their pickup trucks and SUVs, building electrified versions of these vehicles is a great way to boost electric-vehicle adoption. Ford Motors has already unveiled an electric version of its best-selling F-150 pickup truck.
Equipment providers have so much work, Lloyd says, that some of them will soon be turning down contracts. According to industry officials, automakers can easily shell out $200 to $300 million on just one sector of a factory, such as the body shop. Industry consultant Laurie Harbour says that between now and 2023, suppliers will manufacturer equipment for a whopping 37 electric vehicles and this excludes all the equipment they will develop for ICE vehicles. Durr AG, a global mechanical and plant engineering firm that specializes in paint shop equipment, saw its EV business increase by 65% last year, thanks to surging demand in Asia and North America.
Several more companies in the machinery industry have seen significant demand for electric vehicle equipment. Mike LaRose, the CEO of manufacturing and automation firm Kuka Auto Group in the Americas, says the company has been completely booked for the past year and a half. The company has zero free floor space and, thanks to surging demand, the company anticipates that situation to continue.
It would have been hard to imagine decades ago that electric vehicle industry players such as Net Element (NASDAQ: NETE) would trigger growth in other sectors, including machining, but those benefits are manifesting fast.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Ideanomics (NASDAQ: IDEX), a global company focused on driving the adoption of commercial electric vehicles and associated energy consumption, today announced its entry into an agreement to acquire VIA Motors International Inc. (“VIA”) in an all-stock transaction for a 100% ownership stake. The transaction is subject to customary closing conditions, including Ideanomics’ shareholder approval. Headquartered in Orem, Utah, VIA will manufacture electric commercial vehicles including Class 2 through Class 5 cargo vans, trucks and buses. With deep experience in the vehicle electrification market, the company continues to develop business relationships with commercial fleets and distributors in the United States, Canada and Mexico. “This is a transformative deal for Ideanomics,” said Shane McMahon, executive chairman of IDEX. “As we continue to grow into a leader in the commercial EV space, VIA Motors adds valuable brand cachet and an exceptional manufacturing discipline to our portfolio. Bob’s proven executive leadership has helped establish VIA as a market disruptor and we are excited to welcome him and his team to the Ideanomics family.”
To view the full press release, visit https://ibn.fm/vC05w
About Ideanomics Inc.
Ideanomics is a global company focused on the convergence of financial services and industries experiencing technological disruption. The Ideanomics Mobility division is a service provider that facilitates the adoption of electric vehicles by commercial fleet operators through offering vehicle procurement, finance and leasing, and energy management solutions under an innovative sales-to-financing-to-charging (“S2F2C”) business model. Ideanomics Capital is focused on disruptive fintech solutions for the financial services industry. Together, Ideanomics Mobility and Ideanomics Capital provide global customers and partners with leading technologies and services designed to improve transparency, efficiency and accountability, and shareholders with the opportunity to participate in high-potential, growth industries. For more information, visit www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs
- Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions
- Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin filed a U.S. nonprovisional patent application claiming priority to the May 2021 PCT application (https://ibn.fm/MHCO7), and the company also filed two additional international patent applications, bringing the potential to obtain patent coverage in 153 countries (https://ibn.fm/mZ0BL).
According to the company, the International Patent Searching (“IPC”) authority provided a written opinion in support of the novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing. As a result, the nonprovisional patent application includes claims to compositions and methods to support certain elements of the company’s preclinical and research programs.
“Cybin’s portfolio now consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies, and 4 active drug programs targeting major depressive disorder, alcohol use disorder, anxiety and therapy-resistant psychiatric disorders,” said Cybin CEO Doug Drysdale. “We continue to progress our IP portfolio across novel molecules, delivery mechanisms, processes and protocols as we continue to find new and novel discoveries through our preclinical findings, thus expanding and strengthening IP.”
The two international patent applications, governed by the PCT, will grant Cybin the right to file future national applications into treaty member jurisdictions, including important potential markets for the company. In addition, the PCTs cover a library of phenethylamine and derivative drug-development candidates and methods of use.
One of Cybin’s PCT patent applications is in connection with a group of proprietary compounds identified by the company’s research data as being key for further evaluation toward selection as potential therapeutics. The other PCT application includes claims and disclosures toward several other proprietary novel psychedelic compounds, including compounds with positive research data, meeting the company’s internal research metrics. Cybin believes these applications will further strengthen its proprietary CYB005 program, which is targeting therapy-resistant psychiatric disorders, and will provide compositions for further evaluation in future research programs.
Cybin is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its Philadelphia, Pennsylvania-based Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, initiated in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program. “Anpac Bio is proud to have received this accreditation,” said Dr. Pandit, the CLIA Laboratory director and CEO of Anpac Bio in the United States. “The College of American Pathologists (‘CAP’) is the gold standard in medical laboratory accreditation. Through this rigorous inspection process, CAP has certified that Anpac Bio is meeting the highest standards in quality patient care. We have strived from the beginning to lead the industry in quality and innovation. CAP certification is a major milestone along our journey to deliver on our promise of ground-breaking science and commercialization for our novel cancer differentiation analysis (‘CDA’) technology in the United States. We know that the CAP accreditation will only communicate further to our clients, research partners and future patients that Anpac Bio is committed to excellence and exceptional laboratory processes.”
To view the full press release, visit https://ibn.fm/ISNgW
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in the United States and two certified clinical laboratories in China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost & Sullivan’s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnpacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at http://ibn.fm/ANPC
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Research conducted by Penn State College of Medicine has discovered that individuals who are diagnosed with obstructive sleep apnea have a higher risk of sudden death in comparison with individuals who don’t have sleep apnea.
Estimates show that more than one billion people globally suffer from this chronic sleep disorder. The disorder causes a blockage of airflow when an individual is sleeping. This disturbance can also manifest as non-refreshing sleep, heavy snoring, fatigue and excessive daytime sleepiness.
The study was published in “BMJ Open Respiratory Research.”
The researchers conducted a systematic literature review and identified more than 20 studies focusing on sudden death, cardiac death and obstructive sleep apnea. They then analyzed the combined data from this research using meta-analysis, noting that quantitative analysis included a total of more than 40,000 people around the globe.
About 65% of the participants were men, with the mean age being 62. The meta-analysis revealed that people with obstructive sleep apnea were almost twice as likely to experience sudden death. The researchers also found that the chronic sleep disorder also increased the risk of cardiovascular death, noting that the risk increased even more with age.
Dr. Ryan Soose from the UPMC Sleep Medicine Center stated in an interview that untreated sleep apnea patients had higher chances of developing heart disease and high blood pressure, among other health conditions. He added that the risk of sudden death discovered in this study only made timely diagnosis and treatment even more crucial.
One of the authors of the study, Dr. John S. Oh, stated that most individuals didn’t realize the seriousness of an obstructive sleep apnea diagnosis, noting that the condition had fatal consequences.
The central nervous system’s effects on an individual’s sleep cycle may be used to explain the link between the increased risk of sudden death and sleep apnea. As mentioned above, individuals with sleep apnea experience intermittent lack of oxygen, which may cause the central nervous system to increase airflow. This results in an increase in both the diastolic and systolic blood pressure of a person.
The study’s co-author Emily Heilbrunn explains that providing affordable and accessible treatments for patients who suffer from obstructive sleep apnea would help decrease adverse health outcomes for those individuals.
It should be noted that no studies from Africa were included in the meta-analysis, which featured research from South America, Asia, Europe Australia and North America. The researchers assert that more studies need to be conducted in order to determine if the study’s findings apply to populations in Africa.
To address this significant risk factor for sudden death, a number of firms like Vivos Therapeutics Inc. (NASDAQ: VVOS) have developed cutting-edge treatment systems that ensure that people will sleep and breathe properly even with a sleep apnea diagnosis.
NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics Inc. (NASDAQ: VVOS) are available in the company’s newsroom at http://ibn.fm/VVOS
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- UUUU, RadTran to study the recovery of thorium, radium, from existing rare earth carbonate and uranium process streams
- The alliance has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain
- Partnership aims to alleviate major bottleneck in the targeted alpha therapy market
Due to its highly unique licenses, capabilities, and expertise, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is able to supply critical minerals and materials that no other company in the U.S. – or possibly outside of China – is able to do. Energy Fuels’ business revolves around its ability to recover and properly manage uranium and radionuclides in one-of-a-kind ways in the U.S. Energy Fuels is the leading U.S. uranium producer. The company just began producing rare earths by unlocking the value of a mineral called monazite, because this mineral contains the radioactive elements, uranium and thorium. And, UUUU’s most recent strategic partnership takes the company into an entirely new realm: the world of medicine.
Last month Energy Fuels entered into a strategic alliance with RadTran LLC to evaluate the recovery of thorium, as well as possibly radium, from the company’s existing rare earth carbonate and uranium process streams (https://ibn.fm/cT29O). RadTran is a Colorado-based technology development company focused on closing critical gaps in the procurement of medical isotopes for these applications. The two companies will work together to evaluate the potential to use thorium from existing rare earth and uranium process streams for the production of medical isotopes needed for emerging targeted alpha therapy (“TAT”) cancer therapeutics.
“At its heart, the Energy Fuels’ Alliance with RadTran is about maximizing the value and human benefit of our existing uranium and rare earth feeds at the White Mesa Mill,” said UUUU president and CEO Mark S. Chalmers. “Energy Fuels has a long track record of ethically and responsibly processing a wide variety of naturally occurring radioactive materials at the White Mesa Mill for the recovery of uranium and, more recently, rare earths. In our view, recovering medical isotopes from these same streams, that would otherwise be lost to direct disposal, is a great way to maximally use all of our feeds. Indeed, we are essentially replicating China’s ‘monazite plan.’
“China purchases monazite from around the globe, recovers the uranium for use in their nuclear industry, recovers the thorium presumably for use in their nuclear and pharmaceutical industries, and recovers the rare earths for processing into advanced materials needed for various clean energy and advanced technologies,” Chalmers continued. “Our White Mesa Mill is a facility unique to the United States that has the potential to do the same thing at world standards.”
According to the announcement, this new initiative complements Energy Fuel’s existing uranium and RE carbonate businesses, as it involves investigating the recovery of isotopes in existing process streams at the company’s White Mesa Mill in Utah. The alliance, UUUU officials pointed out, “has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain.”
Uranium and thorium are long-lived, naturally occurring radioactive elements that decay into a series of different elements as they lose alpha or beta particles. Certain elements in or derived from the uranium and thorium decay chains emit alpha particles, which are currently being studied by major pharmaceutical companies that are developing therapies to treat cancer on a cellular level while minimizing damage to surrounding healthy tissue. Supplies of these isotopes are limited, however, and existing production methods are costly and unable to scale-up to meet widespread demand as new drugs are developed and approved. This lack of supply is a major obstacle in the research and development of new TAT drugs.
Energy Fuels and its White Mesa Mill may offer a possible solution to this medical supply chain dilemma. The only licensed and operating conventional uranium mill in the United States, the Mill recently began production of RE carbonate from natural monazite sands, which contain thorium-232 and radium-226. Normally these would be disposed of in the Mill’s tailings impoundments, but the new agreement is the first step in recovering these elements for use in medical isotope to treat cancer.
“The Alliance between Energy Fuels and RadTran is remarkable as it aims to alleviate the major bottleneck in the targeted alpha therapy market,” said RadTran founder and CEO Dr. Saleem Drera. “Upon the successful production of these isotopes at the Mill, this alliance will allow pharmaceutical companies who are developing targeted alpha therapies to progress through clinical trials and deploy therapeutics commercially without the hinderance of isotope supply.”
If successful, this alliance could generate significant future cashflow for Energy Fuels in the medical isotope industry, both in human trials over the next several years and once available for widespread cancer treatment. In addition, the company could play a crucial role in supporting cancer research and creating a new, U.S.-based medical supply chain that adheres to the highest global standards for human rights, sustainability, safety and environmental protection.
“We believe Energy Fuels has the potential to create a domestic supply of thorium and possibly radium that can be harvested using RadTran’s technologies for use in the production of the next generation of cancer therapies, a potentially multibillion dollar industry,” said Chalmers. “And we would be accomplishing this in a way that is environmentally beneficial and highly congruent with Energy Fuels’ recycling and sustainability goals. We look forward to working with RadTran on this important initiative.”
For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
LAS VEGAS and VANCOUVER, British Columbia, Aug. 27, 2021 — TAAT ™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT ™ ”) is pleased to announce that Green Global Earth (“GGE”), the exclusive TAAT™ distributor for the U.K. and Ireland who recently placed a CAD $1,075,000 purchase order in addition to its previous CAD $149,000 order as announced in the Company’s August 20, 2021 press release, has issued an additional purchase order for €360,000 (approximately CAD $536,000) for a full shipping container of TAAT™ to be distributed in Australia. Last year, the Company proactively applied for trademarks in Australia as well as dozens of international jurisdictions as described in a press release dated December 31, 2020 .
With Australia having the highest average price of a tobacco cigarette pack in the world (the equivalent of USD $25.12 for a 20-pack of Marlboro, compared to USD $8.00 in the United States 1 ), the Company has long contemplated launching TAAT™ in this market to capitalize on its competitive price point as a non-tobacco product. Current estimates indicate that TAAT™ will retail for approximately 30% less than tobacco cigarettes in Australia. TAAT™ could also gain a competitive advantage in Australia from its ability to be sold in branded packaging, as Australian law requires tobacco cigarettes to be sold in “plain packaging”. Because Australia was the first country in the world to impose plain packaging requirements based on a 2011 law 2 , the Company believes the colourful TAAT™ packs can be especially eye-catching for smokers of legal age in Australia who have become accustomed to the uniform appearance of “plain packaging” for tobacco cigarettes.
At this time, the Company and GGE are in the process of finalizing certain elements of the launch plan for TAAT™ in Australia ( e.g. , taxation, compliant packaging, legal considerations in each state and territory). In the event that GGE’s initial supply of TAAT™ for the U.K. and Ireland approaches depletion before the Australia launch plans are approved, GGE intends to allocate the Australian container order for distribution in the U.K. and Ireland.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ec6bf5a6-27f9-4b82-849e-78ac0e0553f2
Readers using news aggregation services may be unable to view the media above. Please access SEDAR or the Investor Relations section of the Company’s website for a version of this press release containing all published media.
TAAT™ Chief Executive Officer Setti Coscarella commented, “The global interest in TAAT™ from smokers of legal age grows daily, and this Australian opportunity is a testament to that popularity. Australia has been of interest to us as a potential expansion market for TAAT™ for some time now. A major reason for this is our ability to sell TAAT™ in most markets for significantly less than the price of tobacco cigarettes. This will have a larger impact in a market where smokers of legal age pay more per pack than anywhere else in the world. There have been several successive increases to tobacco cigarette prices in Australia in recent years, and we believe that in addition to providing a cost savings, TAAT™ can prove to be a better alternative to tobacco cigarettes for smokers of legal age who aspire to leave nicotine behind. We are very impressed with GGE’s ability to generate interest in TAAT™ in multiple markets globally, which can put TAAT™ in its third continent since it was first launched in Ohio at the end of 2020.”
Sources
1 – https://www.statista.com/chart/15293/price-for-cigarettes-per-country/
2 – https://tobaccotactics.org/wiki/plain-packaging-in-australia/
On behalf of the Board of Directors of the Company,
TAAT ™ GLOBAL ALTERNATIVES INC.
“Setti Coscarella”
Setti Coscarella, CEO and Director
For further information, please contact:
TAAT™ Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatglobal.com
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT ™ Global Alternatives Inc.
The Company has developed TAAT™, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original”, “Smooth”, and “Menthol” varieties. TAAT™’s base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT™ was launched first in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion 1 global tobacco industry.
For more information, please visit http://taatglobal.com .
References
1 British American Tobacco – The Global Market
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT™ in the tobacco industry, in addition to the following: Potential outcomes from GGE’s purchase order for a container of TAAT™, pending confirmation of the legal status of TAAT™ in the states and territories of Australia as a hemp product containing cannabidiol (“CBD”), possible allocation strategies for the Australian container order based on outcomes relating to the prerequisites for launching TAAT™ in Australia. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Statement Regarding Third-Party Investor Relations Firms
Disclosures relating to investor relations firms retained by TAAT™ Global Alternatives Inc. can be found under the Company’s profile on http://sedar.com .
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, and its portfolio of subsidiaries specialized in tree services, debris hauling, biomass recycling, and manufacture of next-generation mulch products and cypress lumber, have the necessary expertise to deal with storms and their negative impact. According to a recent article, SGTM’s vertically integrated operations include three brands “that speak quite clearly to the corporate mission to reduce environmental impact through responsible handling of tree debris rather than burying it in already over-burdened landfills.” The process is efficient and green. “From a mobile command center assessing the damage and plotting a clean-up strategy to truck and rail logistics to create and move feedstock to one of its six production facilities to its retail and wholesale end consumers, SGTM can handle it all.”
To view the full article, visit https://ibn.fm/pHycC
About Sustainable Green Team Ltd.
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit https://ibn.fm/ZdiFf.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- Red White & Bloom Brands Inc. is set to release its Q2 2021 financial results on Monday, August 30, 2021
- The announcement will also be followed by an update on the company’s asset purchases, accompanying notes along with management discussion and analysis
- Q1 2021 saw outstanding performance for the company, with the CEO announcing intentions to finalize its revised asset purchase of the Michigan investee
- The August 30 announcement will give an update to this and more investment decisions for Q2 2021
On July 27, 2021, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) announced its 2021 1st quarter (“Q1”) financial results (https://cnw.fm/tbkqT). Brad Rogers, the Chairman and Chief Executive Officer (“CEO”) of the company, referred to its performance at the time as “Another great quarter for the company.”
When making the announcement, Mr. Rogers also noted that the company would be building on the momentum from Q1, given how much traction it had received for its brand. More so, he pointed out that the company’s priority would be working towards finalizing its revised asset purchase of the Michigan investee in a move to grow sales and revenue.
On Monday, August 30, 2021, the company is set to announce its Q2 2021 financial results (https://cnw.fm/wTiFB). It will give an update on asset purchases and other managerial decisions made over that period, including the Michigan investee mentioned above.
Red White & Bloom Brands Inc. is a pioneer in the cannabis and hemp-derived product lines. It is strategically positioning itself to be among the top three multi-state operators of these products within the American market.
Based in Vancouver, the company is committed to expanding its market reach, a move that has seen investments and pending acquisitions in Michigan and Massachusetts, along with additional plans to enter Florida and California at scale. Red White & Bloom Brands Inc. is set to create the first-ever standardized cannabis facility in the United States, thereby ensuring the superior quality of its products.
For more information, visit the company’s website at www.RedWhiteBloom.com.
NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://cnw.fm/RWBYF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Lexaria Bioscience Corp. (NASDAQ: LEXX) on July 22 announced it had met three primary objectives in its investigation of antiviral drug conversion process outcomes as the drugs are processed with its patented DehydraTECH(TM). “The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVID-19, HIV/AIDS, or other infectious disease-causing viruses, according to the company. The ultimate aim is to form partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics,” reads a recent article. “We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill,” Lexaria CEO Chris Bunka told Investing News Network in a June report. “Our delivery from oral to the bloodstream is as little as two minutes. We’re outrageously fast for oral technology.”
To view the full article, visit: https://cnw.fm/X2OVF
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes. It is planned to be further evaluated for orally administered bioactive molecules, including anti-viral drugs, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at http://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
- The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma
- InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants
- In addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is awaiting the answer to Phase II trial applications in various countries
Dedicated to delivering new therapeutic alternatives as a treatment for conditions with a high unmet medical need, InMed Pharmaceuticals (NASDAQ: INM) is leading the way as a clinical-stage company developing treatment alternatives using rare pharmaceutical-grade cannabinoids. The company’s operations and programs, in particular its ocular program, were the focus of a presentation given by InMed’s President and CEO Eric A. Adams and Senior Vice President of Pre-Clinical Research and Development Dr. Eric Hsu at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021 (https://cnw.fm/TbQ8f).
In the presentation, Adams and Dr. Hsu gave an overview of InMed’s ocular program, consisting of INM-088, a topical eye drop under development for the treatment of glaucoma using cannabinol (“CBN”). This cannabinoid is showing promise for potential neuroprotection and the reduction of intraocular pressure within the eye.
There are over 100 rare cannabinoids that are found in only trace amounts in cannabis. Together, these rare cannabinoids only make up about 1% of the plant’s total biomass – but they are not without their benefits. InMed is currently focused on one cannabinoid, CBN, to meet the unmet needs for medicinal therapeutics for various conditions. The preclinical studies on CBN have shown a promising safety profile and potential therapeutic benefits that exceed tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”).
In addition to INM-088, InMed is currently developing INM-755, a CBN topical cream geared toward treating epidermolysis bullosa, a genetic skin disorder. INM-755 has been evaluated in two Phase I clinical trials of healthy volunteers to date. The Company has also filed Clinical Trial Applications in several countries as a part of Phase II clinical trials for the same indication.
With the availability of rare cannabinoids in the cannabis plant, it is economically impractical for InMed to try and rely solely on the plant as a primary source of these cannabinoids. The Company is developing IntegraSyn, a cannabinoid synthesis manufacturing system, to create these rare cannabinoids in a laboratory setting. The cannabinoids developed in the laboratory setting are bioidentical to the compounds extracted from the natural source.
InMed is also focused on the development of proprietary manufacturing technology to produce rare cannabinoids in the lab and already has a on file to acquire a leading cannabinoid manufacturer.
In late June, InMed entered a non-binding Letter of Intent (“LOI”) to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacturing and commercialization of rare cannabinoids. BayMedica is a revenue-stage biotech company producing high-quality, regulatory compliant rare cannabinoids, including cannabichromene (“CBC”), and providing them as a B2B supplier to distributors and manufacturers.
With a focus on rare cannabinoids and their development in a laboratory setting, InMed is strongly positioned for a prominent role on the U.S. cannabinoid market, a sector valued at $2.3 billion in 2019 and anticipated to grow at a CAGR of 20.4%, resulting in a revenue forecast of $16.4 billion in 2027 (https://cnw.fm/uOehD). Much of this growth can be attributed to the increasing number of medical practitioners prescribing cannabinoids for health-related issues.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
NEW YORK, Aug. 27, 2021 — NetworkNewsAudio – Infobird Co. Ltd. (NASDAQ: IFBD) announces the availability of a broadcast titled, “Going Above and Beyond the Cloud with Latest CRM Innovations.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast
To view the full editorial, please visit: https://ibn.fm/ViYXU
Customer relationship management ( CRM) provided a solution that has now become integral to business. The analyst report points out other advantages that users soon realize, including customer mapping from the outset to interactions even after purchases are completed, a part of the consumer cycle that often gets neglected, as driving adoption.
Other emerging trends include comprehensive cloud-based CRM and integrating artificial intelligence to empower companies to facilitate personalized and proactive engagement with clients, movements that fall into the sweet spot for Infobird Co. Ltd (NASDAQ: IFBD) , a software-as-a-service (SaaS) provider of innovative AI-powered customer-engagement solutions in China. The award-winning company went public in April, raising $25 million in an initial public offering by selling 6.25 million shares at $4 before shares went as high as $11.25 on the opening day of trading.
About Infobird Software Co. Ltd.
Infobird, headquartered in Beijing, China, is a software-as-a-service provider of innovative AI-powered or enabled customer engagement solutions.
For more information about the company, visit www.Infobird.com .
NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” an article quoted Cybin CEO Doug Drysdale discussing the milestone. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector.” Drysdale noted that expanded access to investors is expected to further fuel Cybin’s mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.
To view the full article, visit https://ibn.fm/aqlK8
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with its FDA-cleared NeuroCap(TM) and NeuroEEG(TM), which are already patented in the United States, China and Europe. As the company’s first commercialized devices, they are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. A recent article reads, “Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices. The second, ongoing phase currently focuses on the creation of cloud-based, secure infrastructure to transmit patient data between patients and neurologists. The final and third phase — scheduled for 2021 to 2023 — aims to focus on the use of AI to facilitate diagnostic analysis and increase the consistency, efficiency and accuracy of imaging by neurology specialists. Brain Scientific plans on expanding the vision for telemedicine in neurology with an aim to address the current acute neurologist shortfall throughout the U.S.”
To view the full article, visit: https://ibn.fm/1sVpj
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Radio frequency (“RF”) technology designer and developer AmpliTech Group is leveraging this year’s Nasdaq uplisting and Russell Microcap Index placement to increase its market visibility
- AmpliTech builds and markets communications technology products for the satellite communications, space, telecommunications (5G/6G) and military defense markets
- Markets analysts forecast continued growth over the next five years in the RF component sector, with a CAGR of 13 percent in the multi-billion-dollar sector
- AmpliTech reported a 2021 Q2 55% YOY revenue increase
- A recent follow-on order from an existing global defense and aerospace customer evidences AmpliTech’s growth potential as it continues to build revenues and strategically use its financial resources
The ever-present need for solutions that improve the speed and security of Internet-based technologies is exemplified in the rollout and evolution of 5G wireless communication capabilities worldwide.
State-of-the-art RF signal component developer AmpliTech Group (NASDAQ: AMPG, AMPGW) has seen industry attention to its IP for satellite and 5G communications networks grow following its Nasdaq uplisting earlier this year and its more recent inclusion on the Russell Microcap Index in conjunction with the yearly reconstitution of the index, which took effect June 25.
AmpliTech strengthened its financial standing with over $30M in funding obtained through recapitalization during the winter and spring months and recently celebrated receipt of a follow-on order for its technology from a long-standing customer in the global defense and aerospace sector. The company reported growth in its year-over-year and sequential quarterly revenues and gross profits when it released Q2 financial figures for the period ending June 30.
The company also recently reported a Q2 2021 revenue of $1,024,410 signifying a 55% increase from Q2’20 revenue of $660,699. AmpliTech’s gross profits rose 52.5% to $344,623 in Q2’21 compared to $225,988 in Q2’20. Additionally, the company’s 2021 Q2 results showed record bookings and a record $2.45M backlog (defined as contractually obligated purchase orders with a deadline for delivery).
“As the economy reopens in the wake of COVID-19, our target industries and customers are returning to more normal business and procurement patterns, creating a growing range of revenue opportunities for our Company,” President and CEO Fawad Maqbool stated (https://ibn.fm/H5zz6). “We are proud that the performance, quality and return on investment of our solutions continues to earn repeat business from global leaders.”
AmpliTech is increasing its product development and marketing efforts to meet pent-up demand it has observed building up in the satellite communications, defense and space industries during the course of the COVID-19 pandemic, as well as for needs in other commercial applications.
Analysts at market observer Mordor Intelligence recently forecast growth in the RF components market at a compound annual growth rate (“CAGR”) of 13 percent over the course of the next five years (https://ibn.fm/xwH9a), similar to the pre-pandemic outlook of Grand View Research, Inc., which predicted a 14 percent CAGR to 2025 for revenues of $45.05 billion globally (https://ibn.fm/Ks8Dn).
“RF engineering is incorporated into almost everything helping to transmit or receiving a radio wave across the complete RF spectrum (3 kHz to 300 GHz) that includes cellular phones, radios, Bluetooth, and Wi-Fi technology. With the advent of the Internet of Things (‘IoT’) and even greater wireless connectivity, there will be increased demand for RF components,” Mordor’s report stated.
For more information, visit the company’s website at www.AmpliTechInc.com.
NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG
Safe Harbor Statement
This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s ability to execute its business plan as anticipated; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements because of various factors. Other risks are identified and described in more detail in the “Risk Factors” section of the Company’s filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are partnering to offer key diagnostic and medical consultation services to people across North America who suffer from OSA. The partnership will combine core technologies from each company to develop an accessible platform for patients being screened for OSA; the solution will be available throughout North America and will provide personalized insights for those patients. The end goal is to assist patients in identifying the impact that sleep can have on overall health and help them to receive appropriate treatment for sleep-disordered breathing disorders, including mild to moderate OSA. The solution leverages Vivos’ VivoScore product, which is a biometric ring recording device that enables users to take a simple, comfortable sleep test in the privacy of their own homes. Qualified Empower Sleep personnel will then interpret the test results, which automatically uploaded. Finally, recommended treatments and follow-up visits are then provided. “Our trained providers’ VivoScore sleep test use has increased by more than 300% from just a few weeks ago,” said Vivos chair and CEO Kirk Huntsman in the press release. “What’s more, about half of those patients are testing positive for OSA. Simply put, VivoScore is gaining traction, and we believe that this new cooperative relationship with Empower Sleep will add a vital medical diagnostic and consultative component to our patient-friendly sleep apnea treatment ecosystem. We believe that more screenings and confirmed diagnoses of OSA mean that more patients will seek what is often lifesaving treatment for their OSA, which may include using the Vivos System.”
To view the full press release, visit https://ibn.fm/b1fHF
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in the treatment of more than 19,000 patients worldwide by more than 1,250 trained dentists. Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology, for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) recently announced it is now offering vegan wines as part of its expanding product selections on its U.S. e-commerce platform. Notably, while all wine is plant-based, not all wine is vegan. According to PlantX COO Julia Frank, who is quoted in a recent article, “The alcoholic beverage market is one of the fastest-growing industry segments in the U.S. and globally. The new vertical will allow PlantX to holistically meet customer demands and expectations by expanding its product offerings in line with its mission and values.” Findings of IWSR’s recent Drink Market Analysis reveal that total alcoholic beverage consumption volume increased by +2.0% in 2020, with projections showing that the consumption for 2021 will be up +3.8%. Further, e-commerce alcohol sales in the U.S. are expected to see average annual growth of nearly 45% in value over the next four years. “PlantX’s inclusion of vegan wines as part of its online portfolio, therefore, appears to be leveraging the trends in both the alcoholic beverage market and e-commerce sector.”
To view the full article, visit https://ibn.fm/Z5sXm
About PlantX Life Inc.
As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at https://Investor.PlantX.com.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.